Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
General22 hours agoThe ABC and Ms Lattouf
-
General21 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
General19 hours agoNetanyahu denounces report IDF soldiers had orders to shoot Gaza aid-seekers
-
Noosa News24 hours agoNurses and midwives union at loggerheads with government in wage negotiations